Target General Information
Target ID T91331
Target Name Fibroblast growth factor receptor 3
Synonyms FGFR-3; CD333; Fibroblast growth factor receptor 3; FGFR3
Target Type Clinical Trial
Gene Name FGFR3
Biochemical Class Kinase
UniProt ID FGFR3_HUMAN
Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals
Disease Liver cancer
Example drug BMS-582664 Phase 3 [522676], [542969], [1572592]
Tissue Liver tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.02
Z-score: 0.05
P-value: 8.57E-01
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: -0.03
Z-score: -0.10
P-value: 2.53E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of the persons with other diseases not directly affecting the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Alzheimer's disease
Example drug MK-2461 Phase 1/2 [530708], [1572592]
Tissue Entorhinal cortex
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.08
Z-score: 0.10
P-value: 5.83E-03
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Renal cancer
Example drug Dovitinib Phase 1/2 [536674], [541242], [1572592]
Tissue Kidney
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.99
Z-score: -2.34
P-value: 1.39E-06
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: -0.92
Z-score: -2.40
P-value: 1.83E-47
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Myeloma
Example drug Anti-FGFR3 Phase 1 [550794], [1572592]
Tissue Bone marrow
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.04
Z-score: 0.39
P-value: 6.39E-16
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Retinoblastoma tumor
Example drug PD-0183812 Terminated [547217], [1572592]
Tissue Uvea
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 1.46
Z-score: 8.79
P-value: 9.72E-06
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Target Gene Expression Profiles in Other Tissues of Healthy Individuals
Reference
Ref 547217Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014130)
Ref 550794Clinical pipeline report, company report or official report of Genentech (2011).
Ref 541242(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5962).
Ref 542969(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8097).
Ref 536674A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res. 2008 Apr 1;14(7):2075-81.
Ref 530708MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
Ref 522676ClinicalTrials.gov (NCT00908752) Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC. U.S. National Institutes of Health.
Ref 1572592NCBI GEO: archive for functional genomics data sets--update.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.